izpis_h1_title_alt

A prospective phase II study evaluating intraoperative electrochemotherapy of hepatocellular carcinoma
ID Djokić, Mihajlo (Author), ID Čemažar, Maja (Author), ID Bošnjak, Maša (Author), ID Dežman, Rok (Author), ID Badovinac, David (Author), ID Miklavčič, Damijan (Author), ID Kos, Bor (Author), ID Štabuc, Miha (Author), ID Štabuc, Borut (Author), ID Janša, Rado (Author), ID Popović, Peter (Author), ID Šmid, Lojze (Author), ID Serša, Gregor (Author), ID Trotovšek, Blaž (Author)

.pdfPDF - Presentation file, Download (11,93 MB)
MD5: 2D64E62A853DA73CB9748CC10EE3A466
URLURL - Source URL, Visit https://www.mdpi.com/2072-6694/12/12/3778 This link opens in a new window

Abstract
The aim of this clinical study was to investigate the effectiveness and long-term safety of electrochemotherapy as an emerging treatment for HCC in patients not suitable for other treatment options. A prospective phase II clinical study was conducted in patients with primary HCC who were not suitable for other treatment options according to the Barcelona Clinic Liver Cancer classification. A total of 24 patients with 32 tumors were treated by electrochemotherapy. The procedure was effective, feasible, and safe with some procedure-related side effects. The responses of the 32 treated nodules were: 84.4% complete response (CR), 12.5% partial response (PR), and 3.1% stable disease (SD). The treatment was equally effective for nodules located centrally and peripherally. Electrochemotherapy provided a durable response with local tumor control over 50 months of observation in 78.0% of nodules. The patient responses were: 79.2% CR and 16.6% PR. The median progression-free survival was 12 months (range 2.7–50), and the overall survival over 5 years of observation was 72.0%. This prospective phase II clinical study showed that electrochemotherapy was an effective, feasible, and safe option for treating HCC in patients not suitable for other treatment options.

Language:English
Keywords:electrochemotherapy, hepatocellular carcinoma, open surgery, liver cancer, bleomycin
Work type:Article
Typology:1.01 - Original Scientific Article
Organization:MF - Faculty of Medicine
FE - Faculty of Electrical Engineering
ZF - Faculty of Health Sciences
Publication status:Published
Publication version:Version of Record
Year:2020
Number of pages:14 str.
Numbering:Vol. 12, iss. 12, art. 3778
PID:20.500.12556/RUL-134836 This link opens in a new window
UDC:602
ISSN on article:2072-6694
DOI:10.3390/cancers12123778 This link opens in a new window
COBISS.SI-ID:42834691 This link opens in a new window
Publication date in RUL:03.02.2022
Views:1294
Downloads:333
Metadata:XML RDF-CHPDL DC-XML DC-RDF
:
Copy citation
Share:Bookmark and Share

Record is a part of a journal

Title:Cancers
Shortened title:Cancers
Publisher:MDPI
ISSN:2072-6694
COBISS.SI-ID:517914137 This link opens in a new window

Licences

License:CC BY 4.0, Creative Commons Attribution 4.0 International
Link:http://creativecommons.org/licenses/by/4.0/
Description:This is the standard Creative Commons license that gives others maximum freedom to do what they want with the work as long as they credit the author.
Licensing start date:15.12.2020

Secondary language

Language:Slovenian
Keywords:elektrokemoterapija, hepatocelularni rak, kirurgija

Projects

Funder:ARRS - Slovenian Research Agency
Project number:P3-0003
Name:Razvoj in ovrednotenje novih terapij za zdravljenje malignih tumorjev

Funder:ARRS - Slovenian Research Agency
Project number:P2-0249
Name:Elektroporacija v biologiji, biotehnologiji in medicini

Funder:Other - Other funder or multiple funders
Funding programme:University Clinical Center Ljubljana
Project number:20180061

Similar documents

Similar works from RUL:
Similar works from other Slovenian collections:

Back